Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
'The FDA has provided detailed feedback on the development paths for approval, including a combined clinical study enrolling seasonal flu and bird flu-infected subjects, as such infections occur. We are requesting a Type D meeting with the FDA to specify next steps and look forward to working closely with the Agency to develop TXM for bird flu and seasonal flu,' said C. David Pauza, PhD, Chief Science Officer for Traws Pharma.
'The consistent finding of therapeutic effects of TXM in three animal models of bird flu increases our confidence that this compound should be rapidly progressed for stockpiling and pandemic readiness by government agencies,' said Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC). 'To that end, we have initiated a dialog with the Biomedical Advanced Research and Development Authority (BARDA), the responsible agency for stockpiling for pandemic preparedness in the United States, and we plan to engage with respective international regulatory agencies for the same purpose. With the known history that previous H5N1 virus outbreaks in human populations are associated with death rates of up to 50%1, we believe that these actions should be pursued with great urgency.'
'This initial interaction with the FDA has helped guide the development of TXM as a broad therapeutic against pandemic and seasonal influenza,' commented Iain Dukes, MA DPhil, Interim CEO of Traws Pharma. 'We are committed to progressing the process for stockpiling TXM to prevent any pandemic outbreaks associated with bird flu.'
About Tivoxavir Marboxil
Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza. It has potent in vitro activity against a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent, positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1 bird flu. Seasonal influenza represents an estimated multi-billion dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders2,3, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. We believe that these data support further development of tivoxavir marboxil as a treatment for bird flu and seasonal flu.
Source information:
Per link
Per link
TRAW data on file
About Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, benefits and the regulatory plans for tivoxavir marboxil. The Company has attempted to identify forward-looking statements by terminology including 'believes', 'estimates', 'anticipates', 'expects', 'plans', 'intends', 'may', 'could', 'might', 'will', 'should', 'preliminary', 'encouraging', 'approximately' or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws' clinical trials, our ability to take advantage of expedited regulatory pathways for tivoxavir marboxil, our ability to obtain regulatory approval of tivoxavir marboxil, the expectations of our interactions with regulatory authorities, including both the FDA and BARDA and international regulatory agencies, market conditions, regulatory requirements, changes in government regulation, the extent of the spread and threat of the bird flu, and those discussed under the heading 'Risk Factors' in Traws' filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Traws Pharma Contact:Nora BrennanTraws Pharma, Inc.nbrennan@trawspharma.comwww.trawspharma.com
Investor Contact:Bruce Mackle LifeSci Advisors, LLC646-889-1200bmackle@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
10 minutes ago
- Boston Globe
How hurricanes, fires, and floods put drugs and medical supplies at risk
Advertisement These threats are especially pressing as the Trump administration makes a push to ramp up US drug manufacturing, say the authors of the new research. As part of a broader effort to increase US pharmaceutical factories, President Donald Trump has threatened to impose tariffs on imported medicines, a move that could make the country more reliant on domestically produced supplies. Roughly 40% of finished medications and 80% of active pharmaceutical ingredient components come from abroad, according to US Food and Drug Administration estimates. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'Climate change-driven extreme weather events impose new threats to established vulnerabilities in the US drug supply,' the study's authors wrote. 'Those threats must be examined to be appropriately mitigated.' The analysis used FDA and Federal Emergency Management Agency databases to find drug production facilities in counties with major fire, hurricane, storm, tornado and flood events between 2019 and 2024. California, Florida and North Carolina were home to the largest numbers of facilities in counties with presidential disaster declarations. Advertisement Hurricanes were the most common of the climate-related disasters in areas with pharmaceutical facilities, according to the research. In 2017, Hurricane Maria hit Puerto Rico and disrupted Baxter's saline solution manufacturing facility there. Baxter is a major manufacturer of the sterile salt water widely used in hospitals to deliver medications and keep patients hydrated. The company didn't have backup facilities manufacturing smaller bags of the saline solution, which compounded pre-existing supply issues. Baxter has said it's learned from Maria and now has a more resilient supply chain, citing manufacturing investments and FDA clearance to produce saline outside of the US if needed. Even resilient supply chains are prone to climate shocks, though. Helene flooded Baxter's North Carolina facility, which made 60% of the IV fluid bags used in US hospitals for various functions, including to deliver medicine. Baxter reported earlier this year that the North Carolina plant was back at pre-hurricane production levels, and the FDA said this month that the shortages had resolved. Sarah Ryan, a spokesperson for pharmaceutical industry group PhRMA, says that the industry works with government regulators to avoid shortages. The new research did not determine how often such disasters result in shortages, saying that data wasn't readily available. ©2025 Bloomberg L.P.
Yahoo
25 minutes ago
- Yahoo
The Ultimate Growth Stock to Buy With $1,000 Right Now
Key Points Lyft's stock trades nearly 80% below its IPO price. But it's still generating double-digit sales growth and its profits are soaring. It's also widening its moat with new features and acquisitions. 10 stocks we like better than Lyft › Lyft (NASDAQ: LYFT), the second-largest ride-hailing company in America, hasn't impressed many investors since its public debut six years ago. It went public at $72, but it now trades at around $15. But after that steep drop, it looks like an undervalued growth stock -- and it might just churn a modest $1,000 investment into a lot more money. Why did growth investors lose interest in Lyft? Lyft, which initially only provided its ride-hailing services in the U.S. and Canada, is much smaller than its multinational competitor Uber (NYSE: UBER). Unlike Uber, Lyft doesn't provide any first-party food delivery services -- but it offers mutual perks for subscribers of other food delivery platforms like DoorDash and Grubhub. It also provides bicycle and electric scooter rentals in select cities. Lyft's number of active riders and total revenue surged in 2018, but both metrics cooled off in 2019 before plummeting during the pandemic in 2020. Its growth rates stabilized over the following four years, but it didn't exceed its pre-pandemic ridership levels until 2024. Metric 2018 2019 2020 2021 2022 2023 2024 Active Riders 18.6M 22.9M 12.6M 18.7M 20.4M 22.4M 24.7M Active Rider Growth (YOY) 48% 23% (45%) 48% 9% 10% 10% Revenue $2.2B $3.6B $2.4B $3.2B $4.1B $4.4B $5.8B Revenue Growth (YOY) 103% 68% (35%) 36% 28% 8% 31% Data source: Lyft. YOY = Year-over-year. Lyft's recovery was throttled by stiff competition from Uber, driver shortages, regulatory challenges for gig economy workers, and the challenges of balancing its cost-cutting strategies with the expansion of its platform. Its co-founders, CEO Logan Green and president John Zimmer, also stepped down in 2023. Green was succeeded by David Risher, a former Amazon retail executive who focused on streamlining its business. Lyft's business gradually stabilized, but it didn't impress too many growth-oriented investors because its recovery seemed fragile. Uber, which controls roughly three-quarters of the U.S. ride-hailing market, still generated nearly eight times as much revenue as Lyft in 2024. What's the bull case for Lyft's recovery? Lyft struggled with some post-pandemic growing pains, but it also increased the stickiness of its platform with popular features like its Lyft Pass service for businesses, its subscription-based Price Lock service for recurring trips, its rebooted Lyft Pink membership tier, and its Women+ Connect feature (which matches female and non-binary riders with female and non-binary drivers). Its number of active riders rose to a record high of 26.1 million in the second quarter of 2025. To address its previous driver shortages, Lyft raised its incentives and offered more benefits. To offset the pressure of those higher costs, it provided more high-margin Lyft Black and Lyft SUV services, pared down its lower-margin bicycle and electric scooter rental services, expanded its higher-margin Lyft Media segment (which streams sponsored media content and digital ads across its app and in-car tablets), and pruned its workforce. That's why its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) turned positive in 2023, and why its generally accepted accounting principles (GAAP) earnings and free cash flow (FCF) both turned green in 2024. It's plowing a lot of its cash into big buybacks to boost its earnings per share (EPS) and offset its dilution. That might make Lyft seem like a slower-growth, cost-conscious company, but it still has plenty of ways to expand. Its acquisition of Freenow, which closed on July 31 for about $200 million, will nearly double its total addressable market, add about $1 billion to its annual gross bookings, and diversify its business beyond North America. It's also been testing out autonomous vehicles with Mobileye and May Mobility in select cities, and those vehicles could eventually replace its human drivers while widening its moat against Alphabet's Waymo, Tesla's Robotaxi, and other driverless ride-hailing services. Why is Lyft a great place to park $1,000? From 2024 to 2027, analysts expect Lyft's revenue and adjusted EBITDA to grow at a CAGR of 13% and 29%, respectively. With an enterprise value of $5.05 billion, it looks like a bargain at less than one times this year's sales and 10 times its adjusted EBITDA. Uber trades at 4 times this year's sales and 22 times its adjusted EBITDA. Therefore, Lyft's stock could easily double or triple within the next few years if its growth strategies impress the bulls again. We should take those estimates (which don't fully account for its takeover of Freenow) with a grain of salt. But if you expect Lyft to continue growing in Uber's shadow while balancing its disciplined spending and expansion strategies, it could be a great place to park $1,000 over the next few years. Do the experts think Lyft is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Lyft make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,077% vs. just 185% for the S&P — that is beating the market by 892.55%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Leo Sun has positions in Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, DoorDash, Tesla, and Uber Technologies. The Motley Fool recommends Lyft and Mobileye Global. The Motley Fool has a disclosure policy. The Ultimate Growth Stock to Buy With $1,000 Right Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Signos Unveils First Ever FDA-Cleared Glucose Monitoring Breakthrough for Weight Management, Enabling Millions of Americans to Take Control of Their Health
PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Signos, a purpose-driven metabolic health platform committed to transforming lives through personalized, real-time insights, today announced the launch of Signos Glucose Monitoring System, the first ever FDA-cleared, over-the-counter glucose monitoring system for weight management. At a time when obesity and disease threaten the well-being of millions, Signos is leading the movement to put metabolic health back into the hands of individuals. By integrating Stelo by Dexcom glucose biosensor with an AI-powered platform for deciphering unique metabolisms, Signos enables people to see how food choices, timing, activity, stress, and even sleep affect their bodies in real time — equipping them with the information required to seize their health and make decisions backed by their own biology. "This is more than a product launch — it's a mission," said Sharam Fouladgar-Mercer, CEO and Founder of Signos. "Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn't just about data; it's about giving people ownership over their health and weight journeys in a way never before seen." Key Features and Purpose-Driven Benefits: Igniting the Metabolic Movement with Personalized Data: By tapping into the body's own signals, Signos equips individuals with tools to improve sleep, manage weight, and reduce the risk of chronic disease — not through restriction, but through understanding. Personalized, AI-Driven Insights: Signos translates glucose fluctuations into easy-to-follow, personalized recommendations — transforming raw data into actionable guidance for building healthier everyday habits. Total Body Intelligence: Signos helps users understand how their bodies respond to meals, workouts, sleep, and stress, creating a holistic picture of personal health. Expert Metabolic Monitoring: Signos removes barriers and puts powerful glucose insights into the hands of millions without the need for prescriptions, inflated prices, or hidden hoops. It's real-time metabolic health, made truly accessible. The need for accessible, effective metabolic health solutions has never been greater. With 73.6% of U.S. adults classified as overweight or obese, 88% of Americans classified as metabolically unhealthy, and global diabetes diagnoses projected to reach 1.3 billion by 2050, Signos offers a proactive solution grounded in science and is changing the trajectory of metabolic health by intervening early and guiding users toward meaningful, lasting lifestyle changes. The company aims to help millions monitor their metabolic health and build better habits by leveraging insights based on glucose, the body's primary energy source. Raven-Symoné, actress and advisor, shared, "I've been using Signos for years now and no matter my mental ups and downs it is there to keep me in reality. The reality is things change, levels change, but if you keep an eye on the overall picture you can keep your health in the green. Signos gives me the confidence to enjoy life while being mindful of my body and what it needs." Signos is available now, offering individuals everywhere a revolutionary way to monitor glucose, unlock personalized insights, and take control of their metabolism to build a sustainably healthier life — all from the convenience of their smartphone. For more information, visit View original content to download multimedia: SOURCE Signos
